Last updated: June 2026 · Reviewed June 2026 · Built by the InjectBuddy team
Why do GLP-1 doses increase over time?
GLP-1 doses increase over time because the gut needs weeks to adapt to the drug, and a low starting dose limits the nausea, vomiting and diarrhoea that are worst during dose escalation. Manufacturers print a fixed step-up schedule — semaglutide and tirzepatide both begin far below their target dose and rise every four weeks — so each step trades a little extra appetite suppression for tolerability the body can handle. This guide explains the biology behind the step-up schedule, works through the syringe-unit maths that change at every escalation, and answers the questions people ask most.
- The escalation is about gastrointestinal tolerability, not building potency. Starting low lets gut signalling adapt.
- Each step is held a minimum of 4 weeks; the starting dose is an initiation dose, never a maintenance dose.
- Every dose rise changes your syringe units if you draw from a vial: units = mg ÷ (mg/mL) × 100.
Plan the step-up and convert each dose to units with the GLP-1 titration calculator.
Why the dose escalates at all
GLP-1 receptor agonists slow gastric emptying and dampen appetite signalling. Those same mechanisms drive the side effects: nausea, vomiting and diarrhoea. Introduce a full therapeutic dose on day one and most people would be too unwell to continue. The fix is titration — start at a dose with almost no clinical effect, then climb in fixed steps while the gut adapts.
The evidence is explicit. The Wegovy label instructs prescribers to "follow the dosage escalation… to reduce the risk of gastrointestinal adverse reactions," stepping semaglutide through 0.25, 0.5, 1, 1.7 and 2.4 mg over 16 weeks. In the STEP-1 trial, nausea and diarrhoea were "the most common adverse events… typically transient and mild-to-moderate in severity," subsiding as patients adapted. Tirzepatide tells the same story: in SURMOUNT-1, gastrointestinal events occurred "primarily during dose escalation," which is exactly why the schedule spreads the climb across months rather than weeks.
Receptor adaptation, not tolerance loss
Two things change as you climb. First, the gut's response to slowed emptying blunts over weeks — the same dose that caused nausea at week 2 is tolerable by week 6. Second, the dose itself is rising toward the level that actually drives appetite suppression and glycaemic or weight effect. The starting dose (0.25 mg semaglutide, 2.5 mg tirzepatide) is deliberately sub-therapeutic; the Zepbound label states plainly that "the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." You are not building immunity — you are giving physiology time to catch up to a dose that works.
Week-by-week escalation and the maths behind each step
The table below maps the standard weight-management schedules to the rationale for each step, and to the syringe units a vial user would draw. Units assume a 5 mg/mL multi-dose vial on a U-100 syringe; pen users dial the dose directly and can ignore the units column.
| Weeks | Semaglutide dose | Tirzepatide dose | Why this step | Units @ 5 mg/mL (sema) |
|---|---|---|---|---|
| 1–4 | 0.25 mg | 2.5 mg | Initiation only — lowest GI burden | 5 units |
| 5–8 | 0.5 mg | 5 mg | First effective step once gut adapts | 10 units |
| 9–12 | 1 mg | 7.5 mg | Build appetite effect, re-check tolerability | 20 units |
| 13–16 | 1.7 mg | 10 mg | Approach target; hold if nausea returns | 34 units |
| 17+ | 2.4 mg | 12.5–15 mg | Maintenance / maximum dose | 48 units |
Notice the units column roughly doubles, then doubles again. That is the practical consequence vial users feel: every escalation increases the volume you draw, so a number you memorised at the start is wrong by the next step.
How this is calculated
The conversion is one formula applied at each step. To turn a prescribed dose into a syringe mark:
- Take the prescribed dose in mg.
- Find the vial concentration in mg/mL (total mg in the vial ÷ mL of liquid).
- Volume in mL = dose ÷ concentration.
- Units on a U-100 syringe = mL × 100.
Pen devices remove this step entirely — you dial the dose — but anyone reconstituting a vial must redo the arithmetic at every escalation. The honest caveat: this is a measurement tool. The dose, the schedule, and whether to escalate are medical decisions for your prescriber. The worked examples below verify the maths, nothing more.
Semaglutide 0.25 mg from a vial reconstituted to 5 mg/mL. Volume = 0.25 ÷ 5 = 0.05 mL. Units = 0.05 × 100 = 5 units.
Semaglutide rises to 0.5 mg, same 5 mg/mL vial. Volume = 0.5 ÷ 5 = 0.1 mL. Units = 10 units — double the initiation draw.
Semaglutide 1.7 mg at 5 mg/mL. Volume = 1.7 ÷ 5 = 0.34 mL. Units = 34 units. The same vial now empties far faster than at week 1.
Semaglutide 2.4 mg at 5 mg/mL. Volume = 2.4 ÷ 5 = 0.48 mL. Units = 48 units — nearly ten times the initiation volume.
Same 2.4 mg dose, but a thinner 2.5 mg/mL vial. Volume = 2.4 ÷ 2.5 = 0.96 mL = 96 units. The dose is identical; the draw doubled because concentration halved.
Tirzepatide 2.5 mg from a 10 mg/mL vial. Volume = 2.5 ÷ 10 = 0.25 mL. Units = 0.25 × 100 = 25 units.
Tirzepatide 15 mg from the same 10 mg/mL vial. Volume = 15 ÷ 10 = 1.5 mL — that exceeds a 1 mL syringe, so a higher-concentration vial or a larger barrel is needed: re-check setup.
Common escalation mistakes
The biggest error is treating titration like a race — jumping ahead because the low dose "isn't doing anything." It is not meant to; it is buying tolerability. Skipping steps sharply raises the odds of severe nausea and dehydration, and labels require a minimum hold at each level before moving up.
The second is forgetting that vial strength changes the draw. A memorised unit count from week 1 is wrong by week 5, and a different vial concentration can double or halve the volume for the identical dose. Always re-run the maths after any change to dose, vial strength or syringe size, and confirm it against the GLP-1 titration calculator before drawing.
So, why do GLP-1 doses increase over time?
GLP-1 doses increase over time because the gut needs weeks to adapt to the drug's effect on gastric emptying, and starting low keeps side effects manageable. The step-up is not about building potency — the 0.25 mg semaglutide and 2.5 mg tirzepatide initiation doses are deliberately sub-therapeutic. Each four-week hold lets the body catch up before the next rise toward the maintenance dose. For vial users, every escalation also changes the volume and units to draw, so re-run the numbers at each step with the GLP-1 titration calculator.
FAQs
Why do GLP-1 doses increase over time?
Why do GLP-1 doses go up over time?
Does a higher dose change my syringe units?
How long does each dose step last?
Can I skip ahead to the maintenance dose?
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021. PubMed PMID: 33567185.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. PubMed PMID: 35658024.
- FDA / DailyMed. WEGOVY (semaglutide) prescribing information — dosage escalation table to reduce GI reactions. DailyMed label.
- FDA / DailyMed. OZEMPIC (semaglutide) prescribing information — 0.25 mg initiation then 4-week step-up. DailyMed label.
- FDA / DailyMed. ZEPBOUND (tirzepatide) prescribing information — 2.5 mg initiation, 2.5 mg steps, 15 mg max. DailyMed label.
This guide is for general educational purposes only and does not constitute medical advice. GLP-1 dose and titration schedule are prescribed by a clinician; InjectBuddy only converts a known dose and concentration into syringe volume. Always follow your prescriber's specific instructions.